Table 2.
Summary of DNA methylation markers in lung cancer early diagnosis
| Single/combination marker | Tumor type | Sensitivity(%) | Specificity(%) | Sample type | Reference |
|---|---|---|---|---|---|
|
P16 RARB2 |
Lung cancer | 69 | 87 | Bronchial aspirates | [36] |
| RASSF1A | Lung cancer | 64 | 100 | Carcinoma tissues | [79] |
| Lung cancer | 60 | 90 | Brushing sample | ||
| RASSF1A | Lung cancer | 92 | 100 | Carcinoma tissues | [80] |
| PCDHGB6 + HOXA9 | Lung cancer | 80 | 100 | Brushing sample | |
| RASSF1A | NSCLC | 87 | 75 | Plasma(cirDNA) | [81] |
| RARB2 | Lung cancer | ||||
| SHOX2 | Squamous cell carcinoma | 60 | 90 | Plasma | [82] |
| SHOX2 | Lung cancer | 68 | 95 | Alveolar lavage fluid | [83] |
| SHOX2 | Lung cancer | 65.5 | 90 | Plasma | [56] |
| PTGER4 | Lung cancer | 56.3 | 90 | ||
| SHOX2 + PTGER4 | Lung cancer | 75.6 | 84.8 | ||
| SHOX2 | Lung cancer | 67 | 90 | Plasma | [84] |
| PTGER4 | Lung cancer | 90 | 73 | ||
| SHOX2 + RASSF1A | Lung cancer | 81 | 97.4 | Bronchoalveolar lavage fluid | [85] |
| HOXA9 | NSCLC | 55.2 | 74.3 | Plasma | [86] |